MN 553 FINAL EXAM
Actual Exam 2 — Latest Versions A & B
Advanced Pharmacology &
Pharmacotherapeutics
200 Questions with Correct Detailed Answers & Rationales
Version A: Questions 1–100 | Version B: Questions 101–200
100% VERIFIED ANSWERS
Already Graded A+
BRAND NEW!
Purdue University Global
Graduate Nursing — Master of Science in Nursing
Final Examination Preparation
Purdue University Global | MN 553 | Versions A & B | 200 Questions | Verified A+
,MN 553 Final Exam - Advanced Pharmacology & Pharmacotherapeutics Page 2
VERSION A
Questions 1-100
Total: 100 Questions — Each with Verified Answer & Detailed
Rationale
Section 1: Pharmacokinetics & Pharmacodynamics
Section 2: Pharmacogenomics & Individualized Prescribing
Section 3: Cardiovascular Pharmacology
Section 4: Endocrine Pharmacology
Section 5: Antimicrobial Pharmacology
Section 6: CNS & Psychiatric Pharmacology
Section 7: Prescriptive Practice, Special Populations, & Monitoring
Purdue University Global | MN 553 | Versions A & B | 200 Questions | Verified A+
,MN 553 Final Exam - Advanced Pharmacology & Pharmacotherapeutics Page 3
Section 1: Pharmacokinetics and Pharmacodynamics
Absorption, Distribution, Metabolism, Excretion, & Receptors
Q1: A 62-year-old female graduate nursing student is reviewing pharmacology
concepts for the MN 553 final examination. She asks the preceptor to clarify
the term "bioavailability." Which statement best defines bioavailability as it
applies to prescriptive practice?
A. The rate at which a drug is metabolized by the hepatic cytochrome P450 enzyme
system
B. The fraction of an administered dose of unchanged drug that reaches the systemic
circulation, available at the site of action
C. The volume of distribution divided by the steady-state plasma concentration
D. The total daily dose required to maintain a therapeutic plasma drug level
Correct Answer: B
Rationale: Bioavailability is defined as the fraction (F) of the administered dose that reaches
the systemic circulation unchanged and is available at the site of action. For intravenous drugs,
F = 1.0 (100%); for oral drugs, F is reduced by absorption variability and first-pass hepatic
metabolism. Option A describes hepatic clearance, not bioavailability. Option C describes a
component of volume of distribution calculations. Option D describes a maintenance dose
concept. Understanding bioavailability is critical for prescriptive practice because it influences
route selection (e.g., nitroglycerin IV vs. sublingual), dose conversion between routes, and
generic substitution decisions where the FDA requires 80-125% confidence interval of
AUC/Cmax versus the reference product.
Purdue University Global | MN 553 | Versions A & B | 200 Questions | Verified A+
, MN 553 Final Exam - Advanced Pharmacology & Pharmacotherapeutics Page 4
Q2: A patient with metastatic bone cancer requires around-the-clock analgesia
with morphine. The advanced practice nurse understands that oral morphine
has a bioavailability of approximately 30-40% due to first-pass metabolism.
Which prescriptive strategy best addresses this pharmacokinetic phenomenon?
A. Prescribe the same intravenous and oral morphine dose because first-pass
metabolism does not affect oral bioavailability
B. Prescribe a higher oral dose (typically 2-3 times the IV dose) to account for
reduced bioavailability from first-pass metabolism [CORRECT]
C. Switch to intramuscular morphine to bypass first-pass metabolism and reduce total
daily dose requirements
D. Combine oral morphine with a CYP3A4 inhibitor to enhance bioavailability and
reduce the required oral dose
Correct Answer: B
Rationale: Oral morphine undergoes significant first-pass metabolism by
UDP-glucuronosyltransferases in the liver and gut, reducing bioavailability to approximately
30-40%. To achieve equipotent analgesia, the oral-to-IV morphine conversion ratio is typically
3:1 (i.e., 30 mg oral equals approximately 10 mg IV), meaning the oral dose must be 2-3 times
the IV dose. Option A is incorrect because first-pass metabolism directly reduces oral
bioavailability. Option C is misleading because IM and IV routes both avoid first-pass
metabolism, but IM injection is painful and unnecessary in oncology palliation. Option D is
unsafe because combining morphine with a CYP3A4 inhibitor risks respiratory depression and
sedation without validated bioavailability enhancement. The prescriber must apply
bioavailability concepts to convert between routes safely.
Purdue University Global | MN 553 | Versions A & B | 200 Questions | Verified A+
Actual Exam 2 — Latest Versions A & B
Advanced Pharmacology &
Pharmacotherapeutics
200 Questions with Correct Detailed Answers & Rationales
Version A: Questions 1–100 | Version B: Questions 101–200
100% VERIFIED ANSWERS
Already Graded A+
BRAND NEW!
Purdue University Global
Graduate Nursing — Master of Science in Nursing
Final Examination Preparation
Purdue University Global | MN 553 | Versions A & B | 200 Questions | Verified A+
,MN 553 Final Exam - Advanced Pharmacology & Pharmacotherapeutics Page 2
VERSION A
Questions 1-100
Total: 100 Questions — Each with Verified Answer & Detailed
Rationale
Section 1: Pharmacokinetics & Pharmacodynamics
Section 2: Pharmacogenomics & Individualized Prescribing
Section 3: Cardiovascular Pharmacology
Section 4: Endocrine Pharmacology
Section 5: Antimicrobial Pharmacology
Section 6: CNS & Psychiatric Pharmacology
Section 7: Prescriptive Practice, Special Populations, & Monitoring
Purdue University Global | MN 553 | Versions A & B | 200 Questions | Verified A+
,MN 553 Final Exam - Advanced Pharmacology & Pharmacotherapeutics Page 3
Section 1: Pharmacokinetics and Pharmacodynamics
Absorption, Distribution, Metabolism, Excretion, & Receptors
Q1: A 62-year-old female graduate nursing student is reviewing pharmacology
concepts for the MN 553 final examination. She asks the preceptor to clarify
the term "bioavailability." Which statement best defines bioavailability as it
applies to prescriptive practice?
A. The rate at which a drug is metabolized by the hepatic cytochrome P450 enzyme
system
B. The fraction of an administered dose of unchanged drug that reaches the systemic
circulation, available at the site of action
C. The volume of distribution divided by the steady-state plasma concentration
D. The total daily dose required to maintain a therapeutic plasma drug level
Correct Answer: B
Rationale: Bioavailability is defined as the fraction (F) of the administered dose that reaches
the systemic circulation unchanged and is available at the site of action. For intravenous drugs,
F = 1.0 (100%); for oral drugs, F is reduced by absorption variability and first-pass hepatic
metabolism. Option A describes hepatic clearance, not bioavailability. Option C describes a
component of volume of distribution calculations. Option D describes a maintenance dose
concept. Understanding bioavailability is critical for prescriptive practice because it influences
route selection (e.g., nitroglycerin IV vs. sublingual), dose conversion between routes, and
generic substitution decisions where the FDA requires 80-125% confidence interval of
AUC/Cmax versus the reference product.
Purdue University Global | MN 553 | Versions A & B | 200 Questions | Verified A+
, MN 553 Final Exam - Advanced Pharmacology & Pharmacotherapeutics Page 4
Q2: A patient with metastatic bone cancer requires around-the-clock analgesia
with morphine. The advanced practice nurse understands that oral morphine
has a bioavailability of approximately 30-40% due to first-pass metabolism.
Which prescriptive strategy best addresses this pharmacokinetic phenomenon?
A. Prescribe the same intravenous and oral morphine dose because first-pass
metabolism does not affect oral bioavailability
B. Prescribe a higher oral dose (typically 2-3 times the IV dose) to account for
reduced bioavailability from first-pass metabolism [CORRECT]
C. Switch to intramuscular morphine to bypass first-pass metabolism and reduce total
daily dose requirements
D. Combine oral morphine with a CYP3A4 inhibitor to enhance bioavailability and
reduce the required oral dose
Correct Answer: B
Rationale: Oral morphine undergoes significant first-pass metabolism by
UDP-glucuronosyltransferases in the liver and gut, reducing bioavailability to approximately
30-40%. To achieve equipotent analgesia, the oral-to-IV morphine conversion ratio is typically
3:1 (i.e., 30 mg oral equals approximately 10 mg IV), meaning the oral dose must be 2-3 times
the IV dose. Option A is incorrect because first-pass metabolism directly reduces oral
bioavailability. Option C is misleading because IM and IV routes both avoid first-pass
metabolism, but IM injection is painful and unnecessary in oncology palliation. Option D is
unsafe because combining morphine with a CYP3A4 inhibitor risks respiratory depression and
sedation without validated bioavailability enhancement. The prescriber must apply
bioavailability concepts to convert between routes safely.
Purdue University Global | MN 553 | Versions A & B | 200 Questions | Verified A+
